Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Persongen Biotherapeutics (Suzhou) Co. Ltd. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio has 2 pending office actions currently in progress. These actions are assigned to 2 distinct examiners.
The examiners are located within 1 distinct art unit. HADDAD, MAHER M is the busiest examiner, managing 1 busiest examiner pending office action. The concentration of the 2 pending office actions within the art unit suggests a consistent technical focus for the company's current biotechnological research.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756320 | CD7-CAR-T CELL AND PREPARATION AND APPLICATION THEREOF | DONOGHUE, BRITTNEY ERIN | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756320 | CD7-CAR-T CELL AND PREPARATION AND APPLICATION THEREOF | DONOGHUE, BRITTNEY ERIN | 9d |
| 18261410 | CAR-T CELL TARGETING B7-H3 AND APPLICATION THEREOF IN TREATMENT OF ACUTE MYELOID LEUKEMIA | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18261410 | CAR-T CELL TARGETING B7-H3 AND APPLICATION THEREOF IN TREATMENT OF ACUTE MYELOID LEUKEMIA | HADDAD, MAHER M | — | §112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 17756320 | CD7-CAR-T CELL AND PREPARATION AND APPLICATION THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112Other | Final Rejection | 9d | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial